Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients by Seremet, Teofila et al.
Seremet et al. J Transl Med  (2016) 14:232 
DOI 10.1186/s12967-016-0990-x
RESEARCH
Molecular and epigenetic features 
of melanomas and tumor immune 
microenvironment linked to durable remission 
to ipilimumab-based immunotherapy 
in metastatic patients
Teofila Seremet1,3*† , Alexander Koch2†, Yanina Jansen1, Max Schreuer1, Sofie Wilgenhof1, 
Véronique Del Marmol3, Danielle Liènard3, Kris Thielemans4, Kelly Schats5, Mark Kockx5, Wim Van Criekinge2, 
Pierre G. Coulie6, Tim De Meyer2, Nicolas van Baren6,7 and Bart Neyns1
Abstract 
Background: Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term 
benefit in 10–15 % of patients. A tumor signature that correlates with this survival benefit could help optimizing indi-
vidualized treatment strategies.
Methods: Freshly frozen melanoma metastases were collected from patients treated with either Ipi alone (n: 7) or Ipi 
combined with a dendritic cell vaccine (TriMixDC-MEL) (n: 11). Samples were profiled by immunohistochemistry (IHC), 
whole transcriptome (RNA-seq) and methyl-DNA sequencing (MBD-seq).
Results: Patients were divided in two groups according to clinical evolution: durable benefit (DB; 5 patients) and no 
clinical benefit (NB; 13 patients). 20 metastases were profiled by IHC and 12 were profiled by RNA- and MBD-seq. 325 
genes were identified as differentially expressed between DB and NB. Many of these genes reflected a humoral and 
cellular immune response. MBD-seq revealed differences between DB and NB patients in the methylation of genes 
linked to nervous system development and neuron differentiation. DB tumors were more infiltrated by CD8+ and 
PD-L1+ cells than NB tumors. B cells (CD20+) and macrophages (CD163+) co-localized with T cells. Focal loss of HLA 
class I and TAP-1 expression was observed in several NB samples.
Conclusion: Combined analyses of melanoma metastases with IHC, gene expression and methylation profiling can 
potentially identify durable responders to Ipi-based immunotherapy.
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Background
Melanomas are antigenic tumors that elicit spontaneous 
T cell responses [1, 2]. Immunotherapy aims at increas-
ing these spontaneous responses or at stimulating new 
ones. Most cancer immunotherapy approaches such as 
vaccination, adoptive transfer of anti-tumoral T cells 
and immune checkpoint inhibition were pioneered 
against this malignancy. The latter approach has met 
with remarkable clinical success. Ipilimumab (Ipi), an 
IgG1 monoclonal antibody blocks the T cell inhibi-
tory receptor CTLA-4, and thus counteracts physi-
ological dampening of T cell activation [3]. In patients 
treated with Ipi, a broadening of the anti-tumoral T-cell 
Open Access
Journal of 
Translational Medicine
*Correspondence:  teofila.caplanusi@uzbrussel.be 
†Teofila Seremet and Alexander Koch contributed equally to this work 
1 Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije 
Universiteit Brussel (VUB), Brussels, Belgium
Full list of author information is available at the end of the article
Page 2 of 14Seremet et al. J Transl Med  (2016) 14:232 
repertoire has been documented [4], and in animal 
models anti-CTLA-4 therapy was shown to deplete 
tumor-associated regulatory T cells [5]. Ipi is the first 
drug that improves the overall survival of metastatic 
melanoma patients [6]. Notwithstanding the moder-
ate improvement in overall survival (OS), a remarkably 
durable survival benefit is seen in a subgroup of patients 
(15–20 %), with an inflection point on the survival curve 
occurring after 2–3 years and followed by a plateau [7, 
8]. Different combination strategies to improve the effi-
cacy of Ipi-based therapy are currently being investi-
gated, including combinatorial schemes with cytotoxic 
chemotherapy [9, 10], cancer vaccines [6] as well as 
PD-1 blocking antibodies [11]. TriMixDC-MEL [12], a 
cellular vaccine based on autologous monocyte-derived 
dendritic cells (DC) electroporated with synthetic mes-
senger RNA (mRNA) encoding CD40 ligand, a consti-
tutively active Toll-like receptor 4 and CD70, together 
with mRNA encoding fusion proteins of a human leu-
kocyte antigen (HLA)-class II targeting signal (DC-
LAMP) coupled to a melanoma-associated antigen 
(either MAGE-A3, MAGE-C2, tyrosinase or gp100) 
has anti-tumoral activity in patients with advanced 
melanoma [13]. In a phase II clinical trial, combination 
of TriMixDC-MEL with Ipi resulted in an encourag-
ing objective response rate (38  %) and durable remis-
sion rate (22  % progression-free survival at 2  years) in 
patients with pretreated advanced melanoma [14].
Predicting tumor response to cancer immunotherapy 
has been of major interest. Several groups have identi-
fied a so-called “T-cell inflamed” microenvironment 
as a common hallmark that correlates with response to 
vaccine therapies [15, 16]. This signature was recently 
reported to inversely correlate with the activation of the 
Wnt/ß-catenin signaling pathway [17] and the expres-
sion of COX2 [18]. Furthermore a high level of baseline 
C-reactive protein (CRP) has been correlated with resist-
ance to CTLA-4 blockade by Ipi or tremelimumab [19, 
20]. However, no consistent findings have been reported 
concerning the identification of a tumoral transcriptional 
signature that predicts long-term benefit to Ipi [21, 22]. 
Recent findings indicate that tumors from Ipi responders 
have a higher number of T-cell target antigens that result 
from cancer-associated somatic mutations (often called 
mutated antigens or neoantigens) [4]. Also an IFNg 
immune signature has been shown to predict response 
to anti-PD-1 monoclonal antibodies in melanoma [23] 
as well as in other cancer types [24]. Therefore predic-
tive biomarkers adapted for use in the clinical setting 
are required in order to further optimize individualized 
treatment strategies. In the present study we used immu-
nohistochemistry (IHC), whole-transcriptome sequenc-
ing (RNA-seq), and whole genome methylation analyses 
(by MBD-seq) in order to identify a profile that could 
predict sustained response to Ipi-based immunotherapy.
Methods
Patients and tissue samples
Tissue samples obtained from resected melanoma metas-
tases were collected between January 2011 and May 2013 
from patients who received either Ipi treatment in an 
academic trial carried out in the Universitair Ziekenhuis 
Brussel (http://ClinicalTrials.gov NCT01302496) or Ipi 
outside of a clinical trial after its approval. Informed con-
sent using an ethics committee approved form has been 
obtained from all patients. The Ethics Committee from 
Universitair Ziekenhuis Brussel has approved the col-
lection of samples and the research project. All patients 
signed informed consent for collection/processing and 
publication of the anonymous clinical and research data. 
The fresh tumor samples were divided in 2 or 3 parts 
depending on their size. In general one part was pro-
cessed for formalin-fixed, paraffin-embedded (FFPE) 
preservation, the second part was frozen immediately, 
and the third part was preserved in Qiagen RNAlater sta-
bilization reagent. Samples were collected before or after 
therapy onset (including one sample during the lesion-
regression period). The FFPE samples were used for diag-
nosis confirmation in the Pathology Department of our 
hospital and for automated quantification of immune 
cells with Definiens platform in HistoGeneX Laborato-
ries. Freshly frozen and RNAlater samples were used for 
DNA/RNA extraction.
For the purpose of biomarker analyses, patients were 
divided in two groups depending on their clinical out-
come on Ipi-based therapy: durable clinical benefit (DB; 
patients with a long-term complete or partial response), 
and patients with no clinical benefit (NB; patients with 
progressive disease).
Immunohistochemistry (IHC)
Sequential cryosections (7 µm thick) were obtained from 
frozen OCT-embedded tissue samples, air dried, and 
stored at −80 °C until use. The cryosections were thawed 
and fixed in 4  % paraformaldehyde before staining. 
Endogenous peroxidase activity was blocked with Per-
oxidase Blocking Reagent (Dako Cytomation, Glostrup, 
Denmark). The sections were incubated for 30 min with 
unlabeled primary antibody, washed, and incubated for 
30 min with a secondary polyclonal goat anti-mouse anti-
body coupled to horseradish peroxidase (HRP, Vector 
Laboratories, Burlingame, USA). After washing, bound 
antibodies were detected with 3-amino-9-ethylcarbazole 
and sections were counterstained with hematoxylin. All 
reactions were carried out at room temperature. Staining 
was performed for HE and 12 markers: PanMel, MCSP, 
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CD3, CD8, CD20, CD163, DC-LAMP, Casp-3, Ki-67, 
PHH3, HLA class I, TAP1 and von Willebrand factor 
(vWF). Stained slides were digitized using a Mirax Midi 
scanner (Carl Zeiss MicroImaging, Jena, Germany).
Serial FFPE slides were stained for CD8 and PD-L1 
using in-house validated IHC assays on automated stain-
ing platforms, respectively Ventana Benchmark XT and 
Ultra. After deparaffination and heat induced epitope 
retrieval (HIER), sections were incubated for 32 min with 
unlabeled primary antibody and washed. After applying 
the secondary HRP 3,3′-diaminobenzidine (DAB) detec-
tion system, slides were counterstained with haematoxy-
lin. All stained slides were digitized using a digital slide 
scanner (3DHISTECH, Hungary). Semi-automated CD8 
and PD-L1 quantification (generating an estimated per-
centage of the tumor area stained for a given marker) was 
done using Definiens Tissue Studio (Definiens AG, Ger-
many) according to an in-house developed algorithm. 
Furthermore PD-L1 was semi-quantitatively evaluated 
by a qualified pathologist (blinded for the clinical data), 
who scored the %PD-L1 positive tumor cells (TC) and 
immune cells (IC), including lymphocytes, macrophages 
and dendritic cells. Only the PD-L1 membrane stain-
ing on both TC and IC (at any intensity) was taken into 
account.
DNA and RNA extraction from frozen tissue samples
RNAlater samples or a series of 10 cryosections of 20 µm 
thickness from frozen metastases (when RNAlater sam-
ples were not available) were processed for the simulta-
neous extraction of DNA and RNA by ultracentrifugation 
through a caesium chloride (CsCl) gradient, followed by 
extraction and purification with the NucleoSpin RNA II 
kit. RNA and DNA concentration were assessed by spec-
trophotometry with the NanoDrop tool.
Methyl‑CpG binding domain protein sequencing 
(MBD‑seq)
MBD-sequencing was performed using the MethylCap 
kit (Diagenode, Belgium) as described by De Meyer 
et  al. [25] with some minor modifications. After qual-
ity control (QC) of the extracted genomic DNA with 
the picogreen dsDNA assay (Life Technologies, USA) 
the DNA was sheared using the Covaris S2 ultrasonica-
tor to obtain 200  bp fragments (intensity 5, duty cycle 
10  %, 200 cycles/burst, 190  s). A second QC step was 
performed using the high sensitivity DNA chip (Diagen-
ode) and 300  ng of the sheared DNA of each sample 
was subjected to MBD capture with the MethylCap kit. 
This kit uses the methyl-binding domain of the MeCP2 
protein to enrich for methylated DNA fragments. Next, 
the fragment library for the sequencing experiment 
was prepared using the NEBNext Ultra DNA library 
prep kit (New England Biolabs, USA) and the NEBNext 
Multiplex Oligos for Illumina protocol (index prim-
ers set 1). Adapters were diluted 1/10 before ligation 
and fragments were size selected on an E-Gel EX aga-
rose 2  % gel (Invitrogen, Life Technologies) by cutting 
out 300  ±  50  bp fragments and purifying them with 
the Zymoclean Gel DNA recovery kit (Zymo Research, 
USA). The library was amplified with 13 PCR cycles and 
purified a second time using AMPureXP beads. A high 
sensitivity DNA chip (Agilent Technologies, USA) was 
used for a final QC of the libraries and the concentra-
tions were assessed by qPCR according to the Illumina 
protocol “qPCR quantification protocol guide”. The 
samples were sequenced on an Illumina Genome Ana-
lyzer IIx and the resulting paired-end reads (2 × 50 bp) 
were mapped to the human genome (GRCh37) using 
the Bowtie 1 software [26]. We have previously created 
a map of the human methylome (available online at 
http://www.biobix.be/sample-page/) based on the DNA 
methylation profiling of 80 different cell lines and tissue 
samples. This map was used to delineate a list of a finite 
number of genomic locations where methylation can 
be observed (referred to as methylation cores), thereby 
reducing data complexity. The mapped reads of the dif-
ferent melanoma samples were converted to methylation 
cores and for each core the peak height was calculated as 
the maximum coverage within this core. The full list of 
methylation cores that were used can be found at http://
www.biobix.be/map-of-the-human-methylome/.
RNA‑Seq
The quality control of the extracted total RNA was 
assessed with the RNA 6000 pico chip (Agilent Tech-
nologies) and the Ribogreen assay (Life Technologies). 
Isolation of mRNA, synthesis of cDNA and library prepa-
ration were carried out using the NEBNext Ultra Direc-
tional RNA Library Prep kit and the NEBNext Multiplex 
Oligos for Illumina protocol (index primers set 1, New 
England Biolabs). 14 PCR cycles were used to amplify the 
libraries and the DNA 1000 chip (Agilent Technologies) 
was used for the quality control. The final mRNA concen-
trations were assessed by qPCR (as described for MBD-
seq). The libraries were sequenced on the HiSeq  2000 
platform (2 × 50 bp) and the resulting paired-end reads 
were mapped to the human genome (GRCh37) using 
TopHat 2 [27]. Per-gene count values were calculated 
with the HTSeq-count software [28]. Two technical 
repeats were available for each sample and both read 
counts were summed to combine the repeats. Finally, the 
read counts were aggregated per gene by considering the 
maximal value.
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Data analyses and statistical methodology
The immunohistochemical evaluation of the samples pro-
vided categorical data as well as continuous data when 
quantification of the different cells types was made. The 
Fisher’s exact test was used for the analyses of the contin-
gency tables for the categorical variables. The continuous 
variables were characterized by median, percentile 25 and 
percentile 75, and the Kruskal–Wallis test was used for 
statistical analyses of the IHC results. The analyses were 
performed using R version 3.1.3 and IBM SPSS Statistics 
V 21.0 software. Before the differential analysis both the 
MBD and RNA-seq datasets were filtered to remove low 
coverage data points (average coverage >1 and 25 % of the 
samples must have a coverage >1). The differential anal-
ysis of the MBD and RNA-seq data was performed in R 
(version 3.1.2) with the edgeR [29] package (version 3.8.5), 
which was developed for differential expression analysis of 
RNA-seq data, and which also works well for other types 
of genome-scale count data such as MBD-seq data. Before 
the differential analysis, the MBD-seq data was normal-
ized using quantile normalization (towards average pro-
file, rounding was used to maintain count character of the 
data), while the RNA-seq data was normalized using the 
trimmed mean of M values method available in the edgeR 
package. The complete-linkage clustering method was 
used to create heatmaps of the MBD and RNA-seq data. 
For the gene ontology enrichment analysis, single lists of 
genes ranked by their false discovery rates were entered 
into the GOrilla tool [30].
Results
Patients and samples characteristics
The clinical characteristics of the 18 melanoma patients 
included in the analysis are summarized in Tables  1, 2 
and 3. The median age was 41 years (range 25–67). The 
majority of the patients (61.1  %) received concomitant 
treatment with Ipi and TriMixDC-MEL (Table  1), and 
38.8 % received Ipi mono-therapy. Five patients (27.7 %; 
including four patients treated with Ipi plus TriMixDC-
MEL, and one patient with Ipi mono-therapy) obtained 
a durable complete (CR) or partial tumor response (PR) 
(DB group), and 13 patients (72.2 %) derived no clinical 
benefit (NB group) from Ipi-based therapy.
The 5 patients in the DB group showed a high clini-
cal benefit on Ipilimumab without any other systemic 
therapy as follows: MEL1 showed a PR at week 12 and 
presented only one lymph node of low positivity on 
PET/CT during 22  months; MEL2 had a paradoxical 
response with PD at week 12 (new subcutaneous nod-
ules, bone lesions and a solitary brain metastasis), PR at 
week 36 (received only stereotactic radiotherapy for the 
brain lesion) and during 26  months presented only one 
area metabolically active at the level of C7-T1; MEL3 was 
PR at week 12, CR after 14 months that lasted for 1 year 
(only received 2 Ipi administrations due to immune side 
effects); MEL 4 was PR at week 16, reached CR and after 
4  years remains in CR (last Ipi dose was administered 
3 years ago); MEL 5 was SD at week 12, reached CR after 
8 months, and remains CR after 3 years from starting Tri-
MixIpi (Fig. 1e details the time line for the clinical course 
of DB patients).
The 1 year OS in the DB was 100 %, and 46 % in the NB 
group. The OS at 2 years was 100 % in the DB group, and 
15 % in the NB group. The median OS in the DB group 
has not been reached (1 patient has died after 46 months 
and 4 are alive with a follow-up of 44+, 46+, 50+, 36+ 
months). The median OS in the NB group was 10 months 
where all patients have died. The median PFS in the 2 
Table 1 Demographic and  clinical characteristics of  mela-
noma patients treated with immunotherapy
Ipi Ipilimumab;TriMixIpi TriMixDC combined with Ipi; TriMixDC DC electroporated 
with mRNA encoding CD70, CD40L and a constitutively active toll-like receptor 
4, co-electroporated with mRNA encoding full-length MAGE-A3, MAGE-C2, 
tyrosinase and gp100; DB durable clinical benefit; NB no clinical benefit
Variable Number of patients (n = 18)
Age (years)
Median (range) 41 (25–67)
Gender
 Male 10 (55.5 %)
 Female 8 (44.4 %)
Type of immunotherapy
 TriMixIpi 11 (61.1 %)
 Ipi 7 (38.8 %)
Response to immunotherapy
 DB 5 (27.7 %)
 NB 13 (72.2 %)
Table 2 Samples set characterization
Variable Number of samples (n = 20)
Biopsy time point
 Before treatment 12 (60 %)
 After treatment 8 (40 %)
Tissue type Total Before therapy After therapy
Lymph node 8 (40 %) 7 1
Skin 1 (5 %) 1
Nodule subcutaneous 5 (25 %) 1 4
Liver 1 (5 %) 1
Small intestine 2 (10 %) 1 1
Adrenal gland 1 (5 %) 1
Brain 1 (5 %) 1
Lung 1 (5 %) 1
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groups (DB and NB) was 26, and 5 months respectively 
(data not shown).
The majority of the samples (70 %) were skin, subcuta-
neous or lymph node metastases removed by surgery. The 
remaining samples were from lung, liver, small intestine, 
brain, and adrenal gland metastases (Table  2). Twenty 
samples from 18 patients were evaluated by IHC for 
tumoral and immune markers (Table 3). These included 
the 12 samples analyzed by RNA-seq. Sample MEL19 
was not evaluable for analysis after staining. The same 
12 samples from 12 patients were also processed for the 
whole genome methylation analysis by MBD-seq. This 
group of 12 samples comprised 5 DB and 7 NB patients. 
The five samples in DB group were collected before ther-
apy onset with one exception, a noteworthy sample that 
was collected during the lesion-regression period (MEL 
2). For the NB group, three samples were collected before 
therapy onset and four samples after therapy onset.  
An immune gene expression signature differentiating 
durable clinical benefit from no clinical benefit
Comparative RNA-seq analysis was carried out for the 5 
DB patients and 7 NB patients matched for age and gen-
der. The regressing metastasis MEL2 (Figs.  1e, 2c) was 
illustrative of an effective immune response leading to 
tumor elimination, and the baseline patterns of the other 
4 DB patients clustered with the responding lesion. In the 
NB group this pattern was absent both from the samples 
collected at baseline or at time of progression. The com-
parison between DB and NB resulted in a list of 325 differ-
entially expressed genes with a false discovery rate (FDR) 
<0.05, among which 81 genes had a FDR <0.01 (Fig.  1a). 
Based on their known biological functions, we identified 
64 immune-related genes with FDR <0.05, among which 
25 genes with FDR <0.01 (Fig. 1a). The majority of these 
genes reflected a cellular (FYB, CXCL9, CD69, CD8A, 
CARD11, CD5) and humoral immune response (IGHA1, 
IGHG3, IGHV3-23, IGHGP). The 64 genes were overex-
pressed in tumors from DB vs NB patients. Figure 1b and 
c show the PFS and OS of the 12 patients whose tumors 
were analyzed by RNA-seq. PFS for DB and NB patients 
were 26 and 4  months, respectively. Median OS for NB 
patients was 9 months. In the DB group 1 patient died at 
46 months and the other 4 are still alive (44+, 46+, 50+, 
36+ months). Additionally we looked at the baseline val-
ues for the C-reactive protein (CRP) and lactate dehydro-
genase (LDH), two markers described previously to be 
associated with poor prognosis to Ipi-based therapy. CRP 
and LDH baseline were in the normal range for the DB 
patients. However the majority (5/7) of the NB patients 
also had normal CRP values and 4/7 patients in the NB 
had normal LDH levels (Fig. 1d).
We conclude that in this group of patients treated 
with Ipi  ±  TriMixDC-MEL, clinical outcome is corre-
lated with an immune signature in the tumorsFurther-
more a gene ontology enrichment analysis using the full 
list of 325 genes ranked by their FDR produced a list of 
113 significantly enriched (FDR  <  0.05) biological pro-
cess ontologies (Additional file 1: Table S1 shows the top 
20 biological processes ordered by ascending values of 
FDR). Many of these ontologies were linked to immune 
system processes and immune cell migration: “regu-
lation of immune system process”, “humoral immune 
response”, “cytokine-mediated signaling pathway”, “adap-
tive immune response”, “lymphocyte activation”, “positive 
regulation of leukocyte cell–cell adhesion”.
A differential DNA methylation pattern between durable 
clinical benefit vs. no clinical benefit
The differential analysis of all annotated methylation 
cores (intron, exon and promoter regions) between DB 
and NB resulted in a list of 83 cores, associated with 68 
genes (FDR  <  0.05, Fig.  1f ). Forty-nine of these cores 
were located in introns, 14 in exons and 20 in promoter 
regions. A gene ontology enrichment analysis of the 
differentially methylated cores resulted in a list of 234 
biological process ontologies with an FDR smaller than 
0.001 (Additional file  2: Table S2). The differentially 
methylated genes were enriched for ontologies linked to 
nervous system development, differentiation, function, 
and guidance of neurons: “neuron projection guidance”, 
“regulation of nervous system development”, “regulation 
of neuron differentiation”, “synaptic transmission”.
No overlap was found between the lists of differen-
tially expressed and differentially methylated genes. 
The list of differentially expressed genes was used in the 
(See figure on previous page.) 
Fig. 1 Gene expression analysis for patients with DB and patients with NB from immunotherapy by Ipilimumab ±DC vaccination. a Supervised 
hierarchical clustering of patients with high clinical benefit vs. no clinical benefit using the list of 325 genes that were differentially expressed 
between these two groups (FDR <0.05). On the right, the list of genes with immune-relevant functions (64 with an FDR <0.05 including 25 with 
an FDR <0.01). b PFS of the 12 patients analyzed in a. c OS of the 12 patients analyzed in a. d CRP and LDH baseline levels for the five patients in 
the DB group vs. the seven patients in the NB group; Normal range for CRP <5 mg/L and for LDH 313–618 U/L, the normal range are highlighted 
in transparent green color. e Timeline for the DB patient’s clinical course during Ipi-based immunotherapy. f Differential DNA methylation analysis 
of all annotated methylation cores (intron, exon and promoter regions) between DB and NB. 83 cores associated with 68 genes were differentially 
methylated (FDR <0.001). Forty-nine of these cores were located in introns, 14 in exons and 20 in promoter regions
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unsupervised clustering of the methylation data for these 
genes (and vice versa), but no clustering of the DB and 
NB in separate groups was observed (data not shown).
Analysis of cellular immune infiltrates 
by immunohistochemistry on frozen and FFPE sections
The immune infiltrate was analyzed for 20 samples on fro-
zen sections from 18 patients. The samples were collected 
either before or after therapy onset. In the DB group, six 
samples collected before therapy onset from four patients 
were analyzed. In addition, one DB sample was collected 
during the lesion-regression period. Four NB samples 
collected before therapy and seven samples after ther-
apy were available for IHC analysis. All samples in the 
DB group had a common characteristic: responsiveness 
to immunotherapy, while in the NB group all presented 
baseline or “acquired” resistance to immunotherapy. In 
the latter group, the tumors were collected either before 
therapy or during progression after receiving Ipi-based 
immunotherapy. IHC analysis was performed on frozen 
sections available from the same tumor fragment that 
was used for RNA-seq. The tumor cells were detected 
by immunostaining for tyrosinase  +  gp100  +  Melan-A 
(together PanMel) or MCSP, and the T cells and cytolytic 
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Fig. 2 Infiltration patterns by immune cells in melanoma metastases. Representative sections are shown for the a–c, as well as for the heterogene-
ous infiltration pattern observed in two samples from NB group. a schematic drawing for the T cell infiltration is shown for each pattern. IHC stain-
ings for all Pattern type are shown for: PanMel or MCSP (tumor cells), CD3 (T cells), CD8 (CTLs), CD20 (B cells), CD163 (macrophages). The positive 
cells for all stainings are shown in red on the IHC sections. Zoom in images are shown for the samples MEL 26 (b), MEL 2 (c) and MEL 21 (hetero-
geneous pattern). This illustrates the geographical association of T cells, B cells and macrophages. Additionally the vWF staining (blood vessels) is 
shown for MEL 17—a in order to illustrate the exclusive perivascular T cell localization. Staining for HLA class I and TAP-1 are shown for Pattern B 
and Heterogeneous Pattern. Loss of TAP-1 expression by tumor cells is illustrated for samples MEL 15 and MEL 26 (b) from 2 NB patients. Loss of HLA 
class I expression is shown for MEL 21 (heterogeneous pattern)
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T cells by immunostaining for CD3 and CD8, respectively. 
T cells were present in all samples with the exception 
of MEL17, which showed only T cells with perivascu-
lar localization (staining for von Willebrand factor was 
used to identify the blood vessels in the tissue sections) 
(Fig.  2a). The samples were classified in three categories 
(A to C) reflecting different T-cell infiltration patterns 
(Fig.  2). Group A included the samples with almost no 
T cell infiltration. This pattern was only observed in one 
NB sample (MEL17, Fig. 2a). The majority of the samples 
presented infiltration pattern B (overall low to medium 
number of T cells and the majority confined at the inva-
sive margin): 85.7 % in the DB group and 54.5 % in the NB 
group respectively. No statistically significant differences 
in terms of infiltration pattern were observed between 
the two patient groups (data not shown). Samples with 
a diffuse infiltration (not having the T cells confined to 
the invasive margin) were considered pattern C. The T 
cells were predominantly CD8 positive (Fig. 2a–c). Mac-
rophage infiltration was very similar to that of T cells 
(Fig. 2b, c). An additional noteworthy observation was the 
geographical association of T cells and B cells (Fig. 2b, c). 
CD20+ cells were present in 71.4 % of the samples from 
the DB group, whereas in the NB group only 27.3 % of the 
samples contained CD20+ cells (Table  4, Fisher’s exact 
test, ns p =  0.2). This was prominently displayed by the 
CD20 staining in the MEL 2 sample collected during the 
lesion-regression period. In this particular sample the 
massive T cell infiltration was accompanied by the pres-
ence of B cells and macrophages (Fig.  2c). In the NB 
group, we observed that infiltration pattern C was only 
present in two samples removed after immunotherapy 
onset (MEL 23 and 24; Table  3). In the NB group, two 
samples (MEL 21 and 22) collected before therapy showed 
a mixed infiltration pattern (Table 3). MEL 21 showed a 
mixed A and C pattern, with a loss of HLA class I expres-
sion in the tumor area without T cell infiltration (Fig. 2a, 
heterogeneous pattern region 1). MEL 22 showed a mixed 
B and C pattern, with tumor cells homogeneously stained 
for HLA class I but undetectable transporter for antigen 
presentation TAP-1 (data not shown). This latter pheno-
type, tumor cells positive for class I and negative for TAP-
1, was observed also in sample MEL26, collected from a 
progressing NB patient (Fig.  2b). No statistically signifi-
cant differences were observed in the 2 groups when all 
the above-described characteristics were considered for 
comparisons between the groups (data not shown).
Additionally we used FFPE sections obtained from 
the same tumor samples for automated quantification 
of CD8+ and PD-L1+ cells. The median percentages of 
tumor area stained for CD8 were 4.3 for DB and 1.8 for 
NB (Table 5). Higher CD8+ cell infiltration was observed 
in the DB compared to NB (Table  5). A higher overall 
percentage of PD-L1+ marker area was observed also in 
the DB compared to NB samples (median of 11.1 vs. 3.7). 
Two independent pathologists evaluated the percentage 
of PD-L1+ cells in the tumor component as well as in 
the immune component (Table 5). Again the medians in 
the DB group were numerically higher both for PD-L1+ 
cells in tumor and immune components compared to NB 
group (a median of 17.5 vs. 0 for tumor compartment; 
and 4.5 vs. 1 for the immune compartment). The samples 
were classified based on their CD8 and PD-L1 staining 
pattern: 71.4  % of the samples in the DB group showed 
Table 4 Melanoma metastases immune infiltration in the two clinical benefit groups
Durable benefit No benefit Total
Count % Count % Count %
Pattern of T cell infiltration
 A 0 0 1 9.1 1 5.5
 B 6 85.7 6 54.5 12 66.6
 C 1 14.3 2 18.2 3 16.6
 Heterogenous 0 0 2 18.2 2 11.1
Total 7 100 11 100 18 100
CD20+ cells
 No 2 28.6 8 72.7 10 55.5
 Yes 5 71.4 3 27.3 8 44.4
 Total 7 100 11 100 18 100
CD8_PD-L1 pattern
 A 2 28.6 6 50 8 42.1
 B 5 71.4 6 50 11 57.9
 Total 7 100 12 100 19 100
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a “CD8-PD-L1” pattern (higher number of stained cells 
for CD8/PD-L1 markers and a “moderate-high” overall 
immune infiltrate) compared with only 50 and 30.8  % 
respectively in the NB group (Table 4). None of these dif-
ferences reached a statistically significant difference.
Discussion
Our analysis of melanoma metastases combining RNA 
expression, epigenetic and immunohistochemical pro-
filing allowed to detect features that differ between 
advanced melanoma patients with a durable survival 
benefit from Ipi-based immunotherapy and those who 
had no clinical benefit.
In terms of gene expression profile, these differences 
were predominantly linked to immune system genes, and 
reflected an active B and T cell immune response in DB 
tumors. This signature did not correlate with the over-
all number of T cells present within the tumors, or with 
a certain pattern of infiltration. This suggests that some 
qualitative aspects of the immune response, possibly 
related to immunosuppressive mechanisms, are impor-
tant. The presence of immune cells within the tumors was 
in itself not enough to elicit tumor eradication upon treat-
ment. We considered the immune pattern in the regress-
ing metastasis (MEL2) as being illustrative of an effective 
immune response leading to tumor elimination. Indeed, 
the baseline patterns of pretreatment metastases from 
the patients who responded to the Ipi-based therapy clus-
tered with the responding lesion suggesting that the same 
mechanism of tumor rejection (although at a less effec-
tive level, permitting tumor growth) was already ongoing 
prior to treatment with ipilimumab. In addition, in the NB 
group, the patterns obtained from metastases progressing 
on immunotherapy were similar to those of pretreatment 
samples that afterwards were shown not to respond.
The subcutaneous nodule MEL2 showed few tumor 
cells and a massive infiltration by T and B cells (Fig. 2), 
possibly reflecting its ongoing elimination by the immune 
system. The presence of B cells suggests that a humoral 
immune response may contribute to tumor eradication. 
The role of B cells in anti-tumor immunity is still a mat-
ter of debate [31]. The CD20+ B cells were found in close 
proximity to CD8+ T cells similar to the observations of 
Nielsen et  al. in ovarian cancer, where the presence of 
both CD20+ and CD8+ lymphocytes was associated with 
prolonged survival [32]. Moreover large numbers of peri-
tumoral B cells in metastatic lymph nodes were associ-
ated with favorable outcome in oro- and hypopharyngeal 
carcinoma [33]. During the last 3  years several clinical 
studies have shown a positive association between better 
clinical outcome and high B cell tumor densities in hepa-
tocellular carcinoma [34], metastatic colorectal cancer 
[35], lung cancer [36], and oral squamous cell carcinoma 
[37]. Yuan et  al. showed that patients with pre-existing 
serological immunity (in this case to the NY-ESO1 anti-
gen) and detectable specific CD8+ T cells were twice 
as likely to experience clinical benefit after Ipilimumab 
treatment [38]. In melanoma metastases ectopic lym-
phoid structures were detected and clonal amplification, 
somatic mutations and isotype switching, indicating a 
B-cell response were observed [39].
An additional remarkable observation was the pres-
ence of a mixed pattern of infiltration in two tumor sam-
ples collected before therapy onset from NB patients. 
The absence of immune infiltrate was observed in the 
part of the tumor that presented loss of HLA class I 
expression (MEL 21). Another tumor sample present-
ing a mixed pattern (MEL 22) showed a loss of TAP-1 
expression despite HLA class I expression. Loss or 
down-regulation of proteins involved in antigen pro-
cessing and presentation, such as HLA class I and TAP1, 
Table 5 Automated quantification by  Definiens image 
analysis software for  CD8+ and  PD-L1+ cells on  FFPE sec-
tions. Differentiated tumor component and immune com-
ponent analysis for  PD-L1 expression by  pathologist is 
also shown
Clinical benefit Independent‑samples 
Kruskal–Wallis test
DB NB p value
Definiens CD8 % marker area
Count 7 13 0.492
Valid N 6 10
Median 4.3 1.8
Percentile 25 2.7 0.3
Percentile 75 9.5 4.9
Definiens pdl1 % marker area
Count 7 13 0.299
Valid N 6 6
Median 11.1 3.7
Percentile 25 1.7 0.1
Percentile 75 20.1 8.0
Pathologist evaluation % PDL1 TC
Count 7 13 0.240
Valid N 6 12
Median 17.5 0
Percentile 25 0 0
Percentile 75 20.0 4.5
Pathologist evaluation % PDL1 TC
Count 7 13 0.451
Valid N 6 12
Median 4.5 1.0
Percentile 25 1.0 0
Percentile 75 5.0 4.0
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are well known mechanisms of tumor resistance to 
CTL attack [40–42]. These observations are consistent 
with ongoing selections of antigen-loss variants under 
immune pressure.
Interestingly we also observed a “CD8-PD-L1” pattern 
(higher number of stained cells for CD8/PD-L1 markers) 
in the DB tumors and 1 patient (MEL3) in this group had 
subsequent pembrolizumab treatment and reached CR. 
This patient reached CR first on Ipi-based therapy and had 
a benefit of 26 months, and progressed with new lesions 
that responded completely to pembrolizumab and again 
reached CR after 8  months. This observation is in line 
with the recent data showing that durable clinical benefit 
from Ipi correlates with good outcome from subsequent 
pembrolizumab [43]. Although this suggests a common 
denominator for prediction of response to Ipi and anti-
PD-1 therapy, there are patients with no benefit from Ipi 
that have significant response to anti-PD-1 antibodies after 
failing Ipi [44]. Also the opposite is observed, patient fail-
ing anti-PD-1 can respond to subsequent Ipi [45], thus sug-
gesting that these two types of immunotherapy can have 
complementary mechanisms of action. These observations 
indicate that an individualized approach is required for 
achieving durable disease control to immunotherapy.
Differentially methylated genes were enriched for genes 
linked to nervous system development and neuron differ-
entiation. This result is in line with emerging data showing 
that the ability of melanoma cells to undergo reprogram-
ming to a neural crest-like dedifferentiation status plays a 
role in acquired resistance to treatments, such as targeted 
therapy by BRAF inhibition and immunotherapy [46–50].
We did not find a link between the RNA-seq and MBD-
seq analyses. The differentially expressed genes did not 
show differences in methylation between the DB and NB 
groups, and vice versa, suggesting that DNA methyla-
tion was not the cause of differential expression. On the 
other hand, differential methylation of these loci may be 
involved in e.g. alternative splicing and alternative pro-
moter usage of these genes [51], which cannot be readily 
evaluated using the data at hand.
Conclusion
The comparison between the durable long-term respond-
ers to Ipi-based immunotherapy and patients who did 
not show any benefit from this treatment revealed differ-
ences in gene expression reflecting increased activity of the 
immune system in the tumors from responder patients. 
Moreover the differentially methylated genes between 
these two groups of patients are linked to the develop-
ment and differentiation of neurons, possibly reflecting 
a state of dedifferentiation of the melanoma cells. Our 
results are exploratory findings and we acknowledge 
that definitive conclusions regarding the predictive value 
of this molecular signature cannot be drawn from this 
study because of its small sample size and retrospective 
design. Our aim was to contribute to the general goal of 
the field, which is broad characterization of tumors and 
tumor immune microenvironment in relation with clinical 
outcome in order to identify solid predictive markers for 
immunotherapy.
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